蛋白尿减少作为IgA肾病试验的替代终点
本综述基于流行病学数据及13项对照试验的试验水平分析,评估蛋白尿减少能否作为IgA肾病进展至ESKD的替代终点。结果显示蛋白尿水平及持续时间与肾功能丧失强相关,且治疗对蛋白尿百分比下降的效应与对复合肾脏结局的效应相关,支持其作为合理可能的替代终点用于加速审批。
要点
- 蛋白尿是IgA肾病进展至ESKD最广泛认可且研究充分的风险因素。
- 治疗对蛋白尿百分比下降的效应与对肾脏复合结局的效应相关。
- 蛋白尿减少可作为合理可能的替代终点支持加速审批,需上市后验证。
核心结论
- 数据支持将蛋白尿减少作为IgA肾病中治疗对ESKD进展效应的合理可能替代终点。
研究设计与样本
- 本工作组成立肾脏健康倡议项目,对蛋白尿减少作为替代终点的数据进行关键综述,并纳入13项对照试验的试验水平分析。
主要发现
- 流行病学数据显示蛋白尿水平及持续时间与肾功能丧失呈强且一致的关系。
- 13项对照试验的试验水平分析显示治疗对蛋白尿百分比下降的效应与对复合终点(血清肌酐加倍时间、ESKD或死亡)的效应相关。
临床怎么用
- 在美国,合理可能的替代终点可用于严重或危及生命疾病(如IgA肾病)治疗的加速审批。
- 通过该途径获批的产品需在上市后确证试验中验证临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment's effect on long-term kidney outcomes in IgAN and be used as a basis for approval. Proteinuria was identified as the most widely recognized and well studied risk factor for progression to ESKD in IgAN. The workgroup performed a critical review of the data on proteinuria reduction as a surrogate end point for a treatment's effect on progression to ESKD in IgAN. Epidemiologic data indicate a strong and consistent relationship between the level and duration of proteinuria and loss of kidney function. Trial-level analyses of data from 13 controlled trials also show an association between treatment effects on percent reduction of proteinuria and treatment effects on a composite of time to doubling of serum creatinine, ESKD, or death. We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment's effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.
引用
- Thompson A, Carroll K, A Inker L, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019. PMID: 30635299. doi:10.2215/CJN.08600718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。